Research ArticleOriginal Article
Open Access

Skin and soft tissue infections in hospitalized cancer patients

A retrospective study

Huda M. Al-Mutairi, Oluwaseun Egunsola, Afaf Almutairi, Salha M. Al-Dossary, Rana S. Alshammasi, Dalal S. Al-Dossari and Sheraz Ali
Saudi Medical Journal December 2021, 42 (12) 1333-1340; DOI: https://doi.org/10.15537/smj.2021.42.12.20210624

References

  1. 1.↵
    1. Kofteridis DP,
    2. Valachis A,
    3. Koutsounaki E,
    4. Maraki S,
    5. Mavrogeni E,
    6. Economidou FN, et al.
    Skin and soft tissue infections in patients with solid tumours. Sci World J 2012; 2012: 804518.
    OpenUrl
  2. 2.↵
    1. Szvalb AD,
    2. Rolston KVI
    , editors. Skin and Soft Tissue Infections Among Cancer Patients. Springer International Publishing; 2020. p. 1465–76.
  3. 3.↵
    1. May AK.
    Skin and soft tissue infections. Surg Clin North Am 2009; 89: 403–420.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Sartelli M,
    2. Guirao X,
    3. Hardcastle TC,
    4. Kluger Y,
    5. Boermeester MA,
    6. Raşa K, et al.
    2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg 2018; 13: 58.
    OpenUrl
  5. 5.↵
    1. Ustin JS,
    2. Malangoni MA.
    Necrotizing soft-tissue infections. Infect Dis Clin North Am 2021; 35: 135–155.
    OpenUrl
  6. 6.↵
    1. Lopez FA,
    2. Sanders CV.
    Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis Clin North Am 2001; 15: 671–702.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. DeVita VT,
    2. Hellman S,
    3. Rosenberg S
    1. Pizzo PA,
    2. Meyers J,
    3. Freifeld AG,
    4. Walsh T.
    Infection in the cancer patient. In: DeVita VT, Hellman S, Rosenberg S, editors. Cancer Principle and Practice of Oncology. 8th edition. Philadelphia, Pa (USA): Lippincot Company; 2009. pp. 2292–2337. Available from https://books.google.com.au/books?hl=en&lr=&id=yrBI5zx69X8C&oi=fnd&pg=PA1487&ots=Rc7oxVfPMm&sig=IgceltUu9oWxakg9z1Ixlm_Ux_U&redir_esc=y#v=onepage&q&f=false
  8. 8.↵
    1. Stevens DL,
    2. Bisno AL,
    3. Chambers HF,
    4. Dellinger EP,
    5. Goldstein EJ,
    6. Gorbach SL, et al.
    Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59: e10–e52.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Paydar KZ,
    2. Hansen SL,
    3. Charlebois ED,
    4. Harris HW,
    5. Young DM.
    Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006; 141: 850–854; discussion 855-6.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Khan S,
    2. Dhadda A,
    3. Fyfe D,
    4. Sundar S.
    Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl) 2008; 17: 19–25.
    OpenUrlPubMed
  11. 11.↵
    1. Chathuranga G,
    2. Dissanayake T,
    3. Fernando N,
    4. Wanigatunge C.
    Appropriateness of the empirical antibiotics prescribed and their concordance with National Guidelines for three selected infections among cancer patients in a tertiary care centre in Sri Lanka. Int J Microbiol 2021; 2021: 7572215.
    OpenUrl
  12. 12.↵
    1. Ki V,
    2. Rotstein C.
    Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008; 19: 173–184.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    National Cancer Institute. Common Toxicity Criteria (NCICTC) v2.0 1999. [Updated 1999; Accessed 2021 Sept 02]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf.
  14. 14.↵
    1. Kang CI,
    2. Song JH,
    3. Ko KS,
    4. Chung DR,
    5. Peck KR
    , Asian Network for Surveillance of Resistant Pathogens Study G. Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients. Support Care Cancer 2012; 20: 483–488.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Vartivarian SE,
    2. Papadakis KA,
    3. Palacios JA,
    4. Manning JT,
    5. Anaissie EJ.
    Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia: a new spectrum. Ann Intern Med 1994; 121: 969–973.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Yap DYH,
    2. Yip T
    , editors. Diagnosis and Management of Exit Site Infection in Peritoneal Dialysis Patients. InTech; 2016.
  17. 17.↵
    Queensland Government. Tunnelled Central Venous Catheters. [Updated 2018; Accessed 2021 Aug 15]. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0031/444487/icare-tcvc-guideline.pdf
  18. 18.↵
    1. Mermel LA,
    2. Allon M,
    3. Bouza E,
    4. Craven DE,
    5. Flynn P,
    6. O’Grady NP, et al.
    Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1–45.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Montgomery CP,
    2. David MZ,
    3. Daum RS.
    Host factors that contribute to recurrent staphylococcal skin infection. Curr Opin Infect Dis 2015; 28: 253–258.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Miller LG,
    2. Eells SJ,
    3. David MZ,
    4. Ortiz N,
    5. Taylor AR,
    6. Kumar N, et al.
    Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors. Clin Infect Dis 2015; 60: 753–763.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Adderson EE,
    2. Boudreaux JW,
    3. Hayden RT.
    Infections caused by coryneform bacteria in pediatric oncology patients. Pediatr Infect Dis J 2008; 27: 136–141.
    OpenUrlPubMedWeb of Science
  22. 22.↵
    1. Scanlon MM,
    2. Gazelka HM,
    3. Moeschler SM,
    4. Hoelzer BC,
    5. Hooten WM,
    6. Bendel MA, et al.
    Surgical site infections in cancer patients with intrathecal drug delivery devices. Pain Med 2017; 18: 520–525.
    OpenUrl
  23. 23.
    1. Lawson EH,
    2. Hall BL,
    3. Ko CY.
    Risk factors for superficial vs deep/organ-space surgical site infections: implications for quality improvement initiatives. JAMA Surg 2013; 148: 849–858.
    OpenUrl
  24. 24.
    1. Lieber BA,
    2. Appelboom G,
    3. Taylor BE,
    4. Lowy FD,
    5. Bruce EM,
    6. Sonabend AM, et al.
    Preoperative chemotherapy and corticosteroids: independent predictors of cranial surgical-site infections. J Neurosurg 2016; 125: 187–195.
    OpenUrl
  25. 25.↵
    1. Takimoto K,
    2. Wang Q,
    3. Suzuki D,
    4. Katayama M,
    5. Hayashi Y.
    Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections. Expert Opin Pharmacother 2017; 18: 1027–1034.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords